Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 16
2022 21
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
The following terms were not found in PubMed: jsubsetk, jsubsetaim
Page 1
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Jha MK, Mathew SJ. Jha MK, et al. Am J Psychiatry. 2023 Mar 1;180(3):190-199. doi: 10.1176/appi.ajp.20230025. Am J Psychiatry. 2023. PMID: 36855876 Review.
., remission) remains limited, with significant concerns about side effects (including weight gain, metabolic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especially with long-term use. With the rapidly evolving landscape of antidepressant treatmen …
., remission) remains limited, with significant concerns about side effects (including weight gain, metabolic dysfunction, extrapyramidal sy …
Amantadine in the treatment of Parkinson's disease and other movement disorders.
Rascol O, Fabbri M, Poewe W. Rascol O, et al. Lancet Neurol. 2021 Dec;20(12):1048-1056. doi: 10.1016/S1474-4422(21)00249-0. Epub 2021 Oct 19. Lancet Neurol. 2021. PMID: 34678171 Review.
Other uses of amantadine, such as in the treatment of drug-induced parkinsonism, atypical parkinsonism, Huntington's disease, or tardive dyskinesia, lack a strong evidence base. Future trials should examine its role in the management of motor and non-motor symptoms …
Other uses of amantadine, such as in the treatment of drug-induced parkinsonism, atypical parkinsonism, Huntington's disease, or tardive …
Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics.
Vas C, Jain A, Trivedi M, Jha MK, Mathew SJ. Vas C, et al. Psychiatr Clin North Am. 2023 Jun;46(2):261-275. doi: 10.1016/j.psc.2023.02.012. Epub 2023 Mar 25. Psychiatr Clin North Am. 2023. PMID: 37149344 Review.
Benefits of using atypical antipsychotics for TRD has to be weighted against their potential adverse events, such as weight gain, akathisia, and tardive dyskinesia....
Benefits of using atypical antipsychotics for TRD has to be weighted against their potential adverse events, such as weight gain, akathisia, …
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE; Guideline Subcommittee of the AAN. Pringsheim T, et al. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. Neurology. 2021. PMID: 34782410 Free PMC article. Review.
Gastroparesis.
Cangemi DJ, Lacy BE. Cangemi DJ, et al. Curr Opin Gastroenterol. 2021 Nov 1;37(6):596-601. doi: 10.1097/MOG.0000000000000782. Curr Opin Gastroenterol. 2021. PMID: 34560721 Review.
There is increasing sentiment that gastroparesis should be considered a part of the same spectrum of gastric neuromuscular disorders. The risk of tardive dyskinesia with metoclopramide has likely been significantly overestimated historically. ...SUMMARY: Altered cen …
There is increasing sentiment that gastroparesis should be considered a part of the same spectrum of gastric neuromuscular disorders. The ri …
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
BACKGROUND: Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia. To address the ongoing need for improved symptomatic treatments for individuals with Huntington's disease, valbenazine was …
BACKGROUND: Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive …
Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia.
Crump CJ, Good ME, Abuelazm H, El-Mallakh RS. Crump CJ, et al. Expert Opin Pharmacother. 2023 Jun;24(9):1039-1052. doi: 10.1080/14656566.2023.2208269. Epub 2023 May 1. Expert Opin Pharmacother. 2023. PMID: 37102321 Review.
EXPERT OPINION: Antipsychotics can induce adaptive changes in the brain that predispose patients to future problems such as tardive dyskinesia and supersensitivity psychosis. When pathophysiology of schizophrenia, and a clear understanding of the pharmacology of exi …
EXPERT OPINION: Antipsychotics can induce adaptive changes in the brain that predispose patients to future problems such as tardive …
Dopamine partial agonists: a discrete class of antipsychotics.
Taylor D, Chithiramohan R, Grewal J, Gupta A, Hansen L, Reynolds GP, Pappa S. Taylor D, et al. Int J Psychiatry Clin Pract. 2023 Sep;27(3):272-284. doi: 10.1080/13651501.2022.2151473. Epub 2022 Dec 10. Int J Psychiatry Clin Pract. 2023. PMID: 36495086 Review.
These drugs also share a very low risk of increased prolactin and of weight gain and accompanying metabolic effects. They may also have a relatively low risk of tardive dyskinesia. There is some evidence that they are preferred by patients to dopamine antagonists. . …
These drugs also share a very low risk of increased prolactin and of weight gain and accompanying metabolic effects. They may also have a re …
58 results